NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $113.38 +1.56 (+1.40%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Ligand Pharmaceuticals Stock (NASDAQ:LGND) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ligand Pharmaceuticals alerts:Sign Up Key Stats Today's Range$110.00▼$113.5150-Day Range$97.37▼$113.3852-Week Range$49.79▼$113.51Volume206,878 shsAverage Volume135,952 shsMarket Capitalization$2.04 billionP/E Ratio52.49Dividend YieldN/APrice Target$132.83Consensus RatingBuy Company OverviewLigand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Ligand Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks96th Percentile Overall ScoreLGND MarketRank™: Ligand Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 127th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLigand Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ligand Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth18.16% Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 18.16% in the coming year, from $3.47 to $4.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 52.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 52.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.02.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.56% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 0.39%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.57 Percentage of Shares Shorted5.56% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 0.39%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.70 News SentimentLigand Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold 2,058.62% more of their company's stock than they have bought. Specifically, they have bought $243,475.00 in company stock and sold $5,255,692.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Stock News HeadlinesLigand price target raised to $125 from $110 at BarclaysOctober 29 at 4:20 AM | markets.businessinsider.comLigand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $157.00October 24, 2024 | americanbankingnews.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. October 29, 2024 | Porter & Company (Ad)Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024October 23, 2024 | businesswire.comCritical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To KnowOctober 21, 2024 | benzinga.comStrategic Deals and Royalty Expansion Drive Ligand Pharma’s Promising Growth TrajectoryOctober 19, 2024 | markets.businessinsider.comLigand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...October 10, 2024 | finance.yahoo.comThe Latest Analyst Ratings For Ligand PharmaceuticalsOctober 4, 2024 | benzinga.comSee More Headlines LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $71.42 at the beginning of the year. Since then, LGND shares have increased by 58.8% and is now trading at $113.38. View the best growth stocks for 2024 here. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Tuesday, August, 6th. The biotechnology company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.06 by $0.34. Ligand Pharmaceuticals's revenue for the quarter was up 57.2% compared to the same quarter last year. Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' top institutional shareholders include Stephens Investment Management Group LLC (3.44%), Congress Asset Management Co. (3.36%), Chicago Capital LLC (3.03%) and Rice Hall James & Associates LLC (1.74%). Insiders that own company stock include John L Higgins, Matthew W Foehr, Todd C Davis, Matthew E Korenberg, John W Kozarich, Stephen L Sabba, Octavio Espinoza, Andrew Reardon and Nancy Ryan Gray. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/06/2024Today10/28/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$132.83 High Stock Price Target$157.00 Low Stock Price Target$110.00 Potential Upside/Downside+17.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$5.17 Trailing P/E Ratio52.49 Forward P/E Ratio32.67 P/E GrowthN/ANet Income$52.15 million Net Margins29.69% Pretax Margin39.71% Return on Equity7.91% Return on Assets6.99% Debt Debt-to-Equity RatioN/A Current Ratio16.82 Quick Ratio15.81 Sales & Book Value Annual Sales$133.48 million Price / Sales15.29 Cash Flow$5.33 per share Price / Cash Flow21.29 Book Value$40.39 per share Price / Book2.81Miscellaneous Outstanding Shares18,000,000Free Float17,191,000Market Cap$2.04 billion OptionableOptionable Beta1.00 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:LGND) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.